Recombinant production of authentic human proteins using human cell expression systems
The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.
1. An expression vector, comprising a cassette which comprises the following operably linked expression elements:
(A) a human cytomegalovirus immediate early enhancer element;
(B) a functional human beta-actin promoter;
(C) a human globin gene intron; and
(D) a human signal peptide consisting of a immunoglobulin superfamily 8 signal peptide, or an alpha-fibrinogen signal peptide.
2. The expression vector of claim 1 , further comprising a polynucleotide positioned downstream of the signal peptide and operably linked to elements (A), (B), (C), and (D) of claim 1 .
3. The expression vector of claim 2 , wherein either (i) the polynucleotide is operably linked to a transcription termination signal that is located in the expression vector downstream of the human signal peptide, or (ii) the polynucleotide itself comprises a transcription termination signal.
4. The expression vector of claim 2 , wherein the polynucleotide is operably linked to a CMV immediate early enhancer, a beta-actin promoter, a human globin gene intron, and an immunoglobulin superfamily 8 signal peptide.
5. The expression vector of claim 2 , wherein the polynucleotide is operably linked to a CMV immediate early enhancer, a beta-actin promoter, a human globin gene intron, and an alpha-fibrinogen signal peptide.
6. The expression vector of claim 2 , wherein the polynucleotide encodes a cytokine.
7. The expression vector of claim 6 , wherein the encoded cytokine is selected from the group consisting of Activin A, Activin B, Activin A/2xINHbA, Activin B/2xINHbB, AMH/MIS, Artemin, BDNF, BMP2, BMP15/GDF9B, BMP2/BMP2A, BMP3/Osteogenin, BMP4, BMP4/BMP2B, BMP5, BMP7/OP-1, BMP1, BMP10, BMP15/GDF9B, β-NGF, Cystatin C, Delta 1, EGF, Erythropoietin (EPO), FGF acidic, FGF basic, FGF10, FGF5, FGF7, FGF8b, FLT3 ligand, G-CSF, GDF15, GDF2/BMP9, GDF3, GDF5/BMP14, GDF8/myostatin, GDF9, GDNF, GM-CSF, HGF, HGH, IFN-α2A, IFN-α2B, IFN-γ, IFN-β 1 , IGF I, IGF II, IGF IIv1, IGF IIv2, IL10, IL11, IL12, IL15, IL17/IL17A, IL17F, IL1 β IL2, IL23, IL27, IL28A/IFN-lambda-2, IL28B/IFN-lambda-3, IL29/IFN-lambda-1, IL1β, IL2 IL3, IL32, IL35, IL4, IL5, IL6, IL7, IL8, IL9, Inhibin A/INHa&INHbA, Inhibin B/INHa&INHbB, Inhibin C/INHa&INHbC, Inhibin E/INHa&INHbE, LEFTYB, LEFTY1/LeftyB, M-CSF, mouse CSF, mouse SCF, NODAL, Noggin, NT3 (neurotrophin3), Oncostatin M, PDGFα, PDGFβ, Persephin, SCF, SDF1α, SHH, Somatotropin, TGF β1, TGF β2, TGF 3, TGFβ4/LEFTY2/LeftyA, TNF α, TPOα, VEGF121aa, VEGF165aa, WIF1, WNT1, Wnt10A, Wnt10B/12, Wnt11, Wnt16, Wnt2, Wnt2B/13, Wnt3, Wnt3A, Wnt4, Wnt5A, Wnt5B, Wnt6, Wnt7A, Wnt7B, Wnt8B, and Wnt9A/14.
8. The expression vector of claim 7 , wherein the encoded cytokine is selected from the group consisting of EPO, G-CSF, GM-CSF, IL-2, IL-4, IL-6, M-CSF, Noggin, SCF, Somatotropin, TGFβ1, TNFα, and VEGF-165.
9. A recombinant method for producing an authentic human protein, comprising introducing the expression vector of claim 1 into a human cell, wherein the polynucleotide encodes a human protein and wherein expression of the polynucleotide in the human cell produces an authentic human protein.
10. The recombinant method of claim 9 , wherein the authentic human protein has a similar size, structure, molecular weight, glycosylation pattern, and post-transcriptional modifications to that of a native version of the same human protein.
11. The recombinant method of claim 9 , wherein the polynucleotide encodes a protein selected from the group consisting of a cytokine, albumin, IgG, IgA, IgM, IgD, IgE, alpha-1-proteinase inhibitors, blood pro-coagulation proteins, blood anti-coagulation proteins, thrombolytic agents, anti-angiogenic proteins, alpha.-2-antiplasmins, C-1 esterase inhibitors, apolipoproteins, HDL, LDL, Fibronectin, beta-2-glycoprotein I, plasminogens, plasmin, plasminogen activators, plasminogen inhibitors, plasma protease inhibitors, anti-thrombin III, streptokinases, inter-alpha-trypsin inhibitors, alpha.-2-macroglobulin, amyloid protein, ferritins, pre-albumin, GC-globulin, haemopexin, C3-complement, transferrin, urokinase, and alpha.-1-acid-glycoprotein.
12. The recombinant method of claim 9 , wherein the desired polynucleotide encodes a cytokine.
13. The recombinant method of claim 12 , wherein the encoded cytokine is selected from the group consisting of Activin A, Activin B, Activin AI2xINHbA, Activin B/2xINHbB, AMH/MIS, Artemin, BDNF, BMP2, BMP15/GDF9B, BMP2/BMP2A, BMP3/Osteogenin, BMP4, BMP4/BMP2B, BMP5, BMP7/OP-1, BMP1, BMP10, BMP15/GDF9B, β-NGF, Cystatin C, Delta 1, EGF, Erythropoietin (EPO), FGF acidic, FGF basic, FGF10, FGF5, FGF7, FGF8b, FLT3 ligand, G-CSF, GDF15, GDF2/BMP9, GDF3, GDF5/BMP14, GDF8/myostatin, GDF9, GDNF, GM-CSF, HGF, HGH, IFN-α2A, IFN-α2β, IFN-γ, , IFN β 1 , IGF I, IGF II, IGF IIv1, IGF IIv2, IL10, IL11, IL12, IL15, IL17/IL17A, IL17F, IL1 β IL2, IL23, IL27, IL28A/IFN-lambda-2, IL28B/IFN-lambda-3, IL29/IFN-lambda-1, IL1β, IL2 IL3, IL32, IL35, IL4, IL5, IL6, IL7, IL8, IL9, Inhibin A/INHa&INHbA, Inhibin B/INHa&INHbB, Inhibin C/INHa&INHbC, Inhibin E/INHa&INHbE, LEFTYB, LEFTY1/LeftyB, M-CSF, mouse CSF, mouse SCF, NODAL, Noggin, NT3 (neurotrophin3), Oncostatin M, PDGFα, PDGFβ, Persephin, SCF, SDF1α, SHH, Somatotropin, TGF β1, TGF β2, TGF β3, TGFβ4/LEFTY2/LeftyA, TNF α, TPOα, VEGF121aa, VEGF165aa, WIF1, WNT1, Wnt10A, Wnt10B/12, Wnt11, Wnt16, Wnt2, Wnt2B/13, Wnt3, Wnt3A, Wnt4, Wnt5A, Wnt5B, Wnt6, Wnt7A, Wnt7B, Wnt8B, and Wnt9A/14.
14. The recombinant method of claim 13 , wherein the encoded cytokine is selected from the group consisting of EPO, G-CSF, GM-CSF, IL-2, IL-4, IL-6, M-CSF, Noggin, SCF, Somatotropin, TGFβ1, TNFα, and VEGF-165.
15. The recombinant method of claim 9 , wherein the human cell is HZ-293TS deposited under and bearing the ATCC biological deposit accession number of PTA-10165.
16. A stable human cell line called HZ-293TS deposited under and bearing the ATCC biological deposit accession number of PTA-10165.
17. A human cell that expresses the expression vector of claim 1 .
18. The stable human cell of claim 16 , further comprising the vector of claim 1 .